Russell Broaddus, MD, FCAP, speaks to 360 DX on newly release CAP guidelines to help oncologists and pathologists accurately determine their patients' eligibility for immune checkpoint inhibitors. "It’s kind of meant to be like the Constitution … a living, breathing document," says Dr. Broaddus. "And there are areas that I'm hoping we can update five years from now with more literature."
For the full article click here: 360 DX: CAP Weighs in on dMMR, MSI Assays for Immunotherapy Patient Selection | CAP